Alkaline Citrate Treatment to Lower the Risk of Nephrocalcinosis in Preterm Infants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00249951

Recruitment Status : Completed

First Posted : November 7, 2005

Last Update Posted : July 3, 2012

Sponsor:

Information provided by (Responsible Party):

Prof. Dr. B. Hoppe, University of Cologne

Study Description

Brief Summary:

Preterm infants are at risk to develop nephrocalcinosis. Incidence numbers vary according to birth weight and gestation age. Very low birth weight infants have the highest risk index, with ~ 7-10 % of preterm infants developing nephrocalcinosis in the patient population. We, the researchers at the University of Cologne, and others found significantly decreased urinary citrate excretion (hypocitraturia) to be one of the main risk factors. Hence, we hypothesized, that prophylactic treatment with oral alkaline citrate solution (Shol's solution) would help to 1) increase urinary citrate excretion and 2) help to decrease the incidence of nephrocalcinosis.

Condition or disease	Intervention/treatment	Phase
Nephrocalcinosis	Drug: Alkaline citrate	Phase 3

Study Design


Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	80 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Triple (Participant, Care Provider, Investigator)
Primary Purpose:	Prevention
Study Start Date :	November 2005
Actual Primary Completion Date :	November 2008
Actual Study Completion Date :	November 2008

Resource links provided by the National Library of Medicine

Drug Information available for: Sodium citrate

Genetic and Rare Diseases Information Center resources: Nephrocalcinosis

U.S. FDA Resources

Arms and Interventions

Intervention Details:

Drug: Alkaline citrate
Prophylactic alkaline citrate medication during the first 8 weeks of life versus placebo solution to prevent nephrocalcinosis of prematurity.

Other Name: no brand names, Shol's solution versus placebo solution (NaCl 0.9 %)

Outcome Measures

Primary Outcome Measures :

Prevention of nephrocalcinosis [ Time Frame: First eight weeks of life ]
Prevention of the development of nephrocalcinosis under prophylactic treatment with an alkaline citrate prepration.

Secondary Outcome Measures :

Increase in urinary citrate excretion [ Time Frame: First eight weeks of life ]
Increase in urinary citrate excretion under prophylactic treatment

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	up to 8 Weeks (Child)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Preterm infants < 32 weeks gestation age and < 1500 g birth weight

Exclusion Criteria:

Cardial, renal or gastrointestinal malformations
Chronic renal failure
Therapy with vitamin B6
High dose treatment with furosemide or dexamethasone
Addison's disease
Severe metabolic alkalosis
Worse clinical condition of preterm infant, which makes oral feeding impossible
Participation in other studies

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00249951

Locations


Germany
Prof. Dr. Bernd Hoppe
Cologne, Germany, D-50924

Sponsors and Collaborators

University of Cologne

Investigators


Principal Investigator:	Bernd Hoppe, Prof. Dr.	University Children's Hospital Cologne, Kerpenerstr. 62, D-50924 Cologne, Germany

More Information

Publications:

Sikora P, Roth B, Kribs A, Michalk DV, Hesse A, Hoppe B. Hypocitraturia is one of the major risk factors for nephrocalcinosis in very low birth weight (VLBW) infants. Kidney Int. 2003 Jun;63(6):2194-9.

Hoppe B, Duran I, Martin A, Kribs A, Benz-Bohm G, Michalk DV, Roth B. Nephrocalcinosis in preterm infants: a single center experience. Pediatr Nephrol. 2002 Apr;17(4):264-8.

Hoppe B, Roth B, Bauerfeld C, Langman CB. Oxalate, citrate, and sulfate concentration in human milk compared with formula preparations: influence on urinary anion excretion. J Pediatr Gastroenterol Nutr. 1998 Oct;27(4):383-6.

Hoppe B, Hesse A, Neuhaus T, Fanconi S, Forster I, Blau N, Leumann E. Urinary saturation and nephrocalcinosis in preterm infants: effect of parenteral nutrition. Arch Dis Child. 1993 Sep;69(3 Spec No):299-303.


Responsible Party:	Prof. Dr. B. Hoppe, Head, Division of Pediatric Nephrology, University of Cologne
ClinicalTrials.gov Identifier:	NCT00249951 History of Changes
Other Study ID Numbers:	FG03-157
First Posted:	November 7, 2005 Key Record Dates
Last Update Posted:	July 3, 2012
Last Verified:	June 2012

Keywords provided by Prof. Dr. B. Hoppe, University of Cologne:


nephrocalcinosis premature infants hypocitraturia alcaline citrate therapy Nephrocalcinosis in premature infants

Additional relevant MeSH terms:


Nephrocalcinosis Kidney Diseases Urologic Diseases Calcinosis Calcium Metabolism Disorders Metabolic Diseases	Citric Acid Anticoagulants Calcium Chelating Agents Chelating Agents Sequestering Agents Molecular Mechanisms of Pharmacological Action

To Top